Hepatitis A virus vaccination in persons with hepatitis C virus infection: Consequences of quality measure implementation

Ian A. Rowe, Richard Parker, Matthew J. Armstrong, Diarmaid D. Houlihan, David J. Mutimer – 28 February 2012 – Hepatitis A virus (HAV) superinfection in persons with hepatitis C virus (HCV) infection has been associated with a high mortality rate, and vaccination is recommended. The incidence of HAV is low, and the aim of this study was to determine the mortality risk of HAV superinfection and the consequences of routine vaccination in persons with HCV infection.

The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin‐9/tim‐3 pathway

Rodrigo Liberal, Charlotte R. Grant, Beth S. Holder, Yun Ma, Giorgina Mieli‐Vergani, Diego Vergani, Maria Serena Longhi – 28 February 2012 – In autoimmune hepatitis (AIH), liver‐damaging CD4 T cell responses are associated with defective CD4posCD25pos regulatory T cells (T‐regs). Galectin‐9 (Gal9), a β‐galactosidase–binding protein expressed by T‐regs, is key to their function, inhibiting T helper 1 immune responses by binding T cell immunoglobulin and mucin domain 3 (Tim‐3) on CD4 effector cells.

Liver phospholipid transfer protein (PLTP) expression with a PLTP‐null background promotes very low‐density lipoprotein production in mice

Amirfarbod Yazdanyar, Xian‐Cheng Jiang – 24 February 2012 – It is known that plasma phospholipid transfer protein (PLTP) activity influences lipoprotein metabolism. The liver is one of the major sites of lipoprotein production and degradation, as well as of PLTP expression. To address the impact of liver‐expressed PLTP on lipoprotein metabolism, we created a mouse model that expresses PLTP in the liver acutely and specifically, with a PLTP‐null background. This approach in mouse model preparations can also be used universally for evaluating the function of many other genes in the liver.

Subscribe to